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Introduction
Fucosylation is a process by which fucose sugar groups
are added to cell surface receptors. This process is
mediated by fucosyl transferases that attach terminal
fucose groups to acceptor molecules on the cell surface.
Fucosylation of cord blood stem cells and human regu-
latory T cells (Treg) were shown to enhance cord blood
engraftment and Treg homing to inflamed tissues. Since
tumor tissues have a component of inflammation, we
hypothesized that fucosylation of antigen specific cyto-
toxic T lymphocytes (CTL) ex vivo will enhance their
migration into tumors and subsequent killing of tumor
cells. Specifically we tested whether ex vivo fucosylation
of CTL that target the HLA-A2 restricted HER2/neu-
derived peptide, E75, enhances E75-CTL migration and
cytotoxic functions.
Methods
E75-CTL were generated using standard methodologies.
Fucosylation was achieved by co-culturing T cells with
FTVII enzyme (Targazyme) and GDP fucose. To study
migration, fucosylated and non-fucosylated E75-CTL were
passed through chambers that were coated with a HUVEC
barrier and migrated CTL were detected using cell fluores-
cence. To examine CTL surface markers, cells were
stained for standard co-stimulatory and adhesion mole-
cules and were analyzed using flow cytometry. Calcein
AM cytotoxicity assays were used to determine the effects
of fucosylation on CTL killing of target cells. For in vivo
assessment of fucosylation on activity of CTL, NSG mice
were engrafted orthotopically with SKBR3-A2 human
breast cancer cells and were treated with intravenous
injections of 106 fucosylated or non-fucosylated E75-CTL.
Mice were examined twice weekly and were sacrificed on
week 5 for tissue analysis.
Results
Fucosylated E75-CTL showed 1.6-fold higher migration
through the HUVEC cell barrier compared to non-fuco-
sylated E75-CTL (MFI=14,264 vs. 8,926). Analysis of T
cell surface expression of chemokine/adhesion molecules
showed approximately a 5-fold increase in CD49d and
CD195, and 50% increase in CXCR1 and CXCR3 follow-
ing fucosylation. Fucosylation enhanced the cytotoxicity
of E75-CTL against E75-pulsed T2 targets (cytotoxi-
city=33% vs. 25%). In vivo experiments using SKBR3-A2
breast cancer xenografts showed that fucosylated
E75-CTL reduced SKBR3-A2 tumor size by 20%, in
comparison with 5% reduction in the tumor size by
non-fucosylated E75-CTL. Lastly, flow cytometry showed a
2-fold increase in the frequency of human CD45+ lympho-
cytes in the primary tumor following fucosylation.
Conclusions
Fucosylation enhances the migration and cytotoxic func-
tions of E75-CTL. Our data demonstrate a novel approach
to enhance the efficacy of antigen specific T cells that
could be used in adoptive cellular immunotherapy
approaches for breast cancer.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P2
Cite this article as: Qiao et al.: Fucosylation enhances activity of
cytotoxic T lymphocytes against breast cancer. Journal for
ImmunoTherapy of Cancer 2015 3(Suppl 2):P2.
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Qiao et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P2
http://www.immunotherapyofcancer.org/content/3/S2/P2
© 2015 Qiao et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
